Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial

Bertram Pitt, Stefan D. Anker, David A. Bushinsky, Dalane W. Kitzman, Faiez Zannad, I. Zu Huang

Research output: Contribution to journalArticle

198 Citations (Scopus)

Abstract

Aims To evaluate efficacy and safety of RLY5016 (a non-absorbed, orally administered, potassium [K +]-binding polymer) on serum K + levels in patients with chronic heart failure (HF) receiving standard therapy and spironolactone. Methods and resultsOne hundred and five patients with HF and a history of hyperkalaemia resulting in discontinuation of a reninangiotensinaldosterone system inhibitor/blocker and/or beta-adrenergic blocking agent or chronic kidney disease (CKD) with an estimated glomerular filtration rate of + was ≤5.1 mEq/L. Endpoints included the change from baseline in serum K + at the end of treatment (primary); the proportion of patients with hyperkalaemia (K + >5.5 mEq/L); and the proportion titrated to spironolactone 50 mg/day. Safety assessments included adverse events (AEs) and clinical laboratory tests. RLY5016 (n 55) and placebo (n 49) patients had similar baseline characteristics. At the end of treatment, compared with placebo, RLY5016 had significantly lowered serum K + levels with a difference between groups of -0.45 mEq/L (P <0.001); a lower incidence of hyperkalaemia (7.3 RLY5016 vs. 24.5 placebo, P 0.015); and a higher proportion of patients on spironolactone 50 mg/day (91 RLY5016 vs. 74 placebo, P 0.019). In patients with CKD (n 66), the difference in K + between groups was -0.52 mEq/L (P 0.031), and the incidence of hyperkalaemia was 6.7 RLY5016 vs. 38.5 placebo (P 0.041). Adverse events were mainly gastrointestinal, and mild or moderate in severity. Adverse events resulting in study withdrawal were similar (7 RLY5016, 6 placebo). There were no drug-related serious AEs. Hypokalaemia (K +

Original languageEnglish
Pages (from-to)820-828
Number of pages9
JournalEuropean Heart Journal
Volume32
Issue number7
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Potassium
Heart Failure
Placebos
Hyperkalemia
Safety
Spironolactone
Chronic Renal Insufficiency
Serum
Adrenergic beta-Antagonists
Hypokalemia
Incidence
patiromer
Glomerular Filtration Rate
Polymers
Therapeutics
Pharmaceutical Preparations

Keywords

  • Aldosterone antagonist
  • Chronic kidney disease
  • Heart failure
  • Hyperkalaemia
  • Potassium-binding polymer
  • RLY5016

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. / Pitt, Bertram; Anker, Stefan D.; Bushinsky, David A.; Kitzman, Dalane W.; Zannad, Faiez; Huang, I. Zu.

In: European Heart Journal, Vol. 32, No. 7, 04.2011, p. 820-828.

Research output: Contribution to journalArticle

Pitt, Bertram ; Anker, Stefan D. ; Bushinsky, David A. ; Kitzman, Dalane W. ; Zannad, Faiez ; Huang, I. Zu. / Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. In: European Heart Journal. 2011 ; Vol. 32, No. 7. pp. 820-828.
@article{e9bdcde8a1d2448bb43479d9b7f31e2d,
title = "Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial",
abstract = "Aims To evaluate efficacy and safety of RLY5016 (a non-absorbed, orally administered, potassium [K +]-binding polymer) on serum K + levels in patients with chronic heart failure (HF) receiving standard therapy and spironolactone. Methods and resultsOne hundred and five patients with HF and a history of hyperkalaemia resulting in discontinuation of a reninangiotensinaldosterone system inhibitor/blocker and/or beta-adrenergic blocking agent or chronic kidney disease (CKD) with an estimated glomerular filtration rate of + was ≤5.1 mEq/L. Endpoints included the change from baseline in serum K + at the end of treatment (primary); the proportion of patients with hyperkalaemia (K + >5.5 mEq/L); and the proportion titrated to spironolactone 50 mg/day. Safety assessments included adverse events (AEs) and clinical laboratory tests. RLY5016 (n 55) and placebo (n 49) patients had similar baseline characteristics. At the end of treatment, compared with placebo, RLY5016 had significantly lowered serum K + levels with a difference between groups of -0.45 mEq/L (P <0.001); a lower incidence of hyperkalaemia (7.3 RLY5016 vs. 24.5 placebo, P 0.015); and a higher proportion of patients on spironolactone 50 mg/day (91 RLY5016 vs. 74 placebo, P 0.019). In patients with CKD (n 66), the difference in K + between groups was -0.52 mEq/L (P 0.031), and the incidence of hyperkalaemia was 6.7 RLY5016 vs. 38.5 placebo (P 0.041). Adverse events were mainly gastrointestinal, and mild or moderate in severity. Adverse events resulting in study withdrawal were similar (7 RLY5016, 6 placebo). There were no drug-related serious AEs. Hypokalaemia (K +",
keywords = "Aldosterone antagonist, Chronic kidney disease, Heart failure, Hyperkalaemia, Potassium-binding polymer, RLY5016",
author = "Bertram Pitt and Anker, {Stefan D.} and Bushinsky, {David A.} and Kitzman, {Dalane W.} and Faiez Zannad and Huang, {I. Zu}",
year = "2011",
month = "4",
doi = "10.1093/eurheartj/ehq502",
language = "English",
volume = "32",
pages = "820--828",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial

AU - Pitt, Bertram

AU - Anker, Stefan D.

AU - Bushinsky, David A.

AU - Kitzman, Dalane W.

AU - Zannad, Faiez

AU - Huang, I. Zu

PY - 2011/4

Y1 - 2011/4

N2 - Aims To evaluate efficacy and safety of RLY5016 (a non-absorbed, orally administered, potassium [K +]-binding polymer) on serum K + levels in patients with chronic heart failure (HF) receiving standard therapy and spironolactone. Methods and resultsOne hundred and five patients with HF and a history of hyperkalaemia resulting in discontinuation of a reninangiotensinaldosterone system inhibitor/blocker and/or beta-adrenergic blocking agent or chronic kidney disease (CKD) with an estimated glomerular filtration rate of + was ≤5.1 mEq/L. Endpoints included the change from baseline in serum K + at the end of treatment (primary); the proportion of patients with hyperkalaemia (K + >5.5 mEq/L); and the proportion titrated to spironolactone 50 mg/day. Safety assessments included adverse events (AEs) and clinical laboratory tests. RLY5016 (n 55) and placebo (n 49) patients had similar baseline characteristics. At the end of treatment, compared with placebo, RLY5016 had significantly lowered serum K + levels with a difference between groups of -0.45 mEq/L (P <0.001); a lower incidence of hyperkalaemia (7.3 RLY5016 vs. 24.5 placebo, P 0.015); and a higher proportion of patients on spironolactone 50 mg/day (91 RLY5016 vs. 74 placebo, P 0.019). In patients with CKD (n 66), the difference in K + between groups was -0.52 mEq/L (P 0.031), and the incidence of hyperkalaemia was 6.7 RLY5016 vs. 38.5 placebo (P 0.041). Adverse events were mainly gastrointestinal, and mild or moderate in severity. Adverse events resulting in study withdrawal were similar (7 RLY5016, 6 placebo). There were no drug-related serious AEs. Hypokalaemia (K +

AB - Aims To evaluate efficacy and safety of RLY5016 (a non-absorbed, orally administered, potassium [K +]-binding polymer) on serum K + levels in patients with chronic heart failure (HF) receiving standard therapy and spironolactone. Methods and resultsOne hundred and five patients with HF and a history of hyperkalaemia resulting in discontinuation of a reninangiotensinaldosterone system inhibitor/blocker and/or beta-adrenergic blocking agent or chronic kidney disease (CKD) with an estimated glomerular filtration rate of + was ≤5.1 mEq/L. Endpoints included the change from baseline in serum K + at the end of treatment (primary); the proportion of patients with hyperkalaemia (K + >5.5 mEq/L); and the proportion titrated to spironolactone 50 mg/day. Safety assessments included adverse events (AEs) and clinical laboratory tests. RLY5016 (n 55) and placebo (n 49) patients had similar baseline characteristics. At the end of treatment, compared with placebo, RLY5016 had significantly lowered serum K + levels with a difference between groups of -0.45 mEq/L (P <0.001); a lower incidence of hyperkalaemia (7.3 RLY5016 vs. 24.5 placebo, P 0.015); and a higher proportion of patients on spironolactone 50 mg/day (91 RLY5016 vs. 74 placebo, P 0.019). In patients with CKD (n 66), the difference in K + between groups was -0.52 mEq/L (P 0.031), and the incidence of hyperkalaemia was 6.7 RLY5016 vs. 38.5 placebo (P 0.041). Adverse events were mainly gastrointestinal, and mild or moderate in severity. Adverse events resulting in study withdrawal were similar (7 RLY5016, 6 placebo). There were no drug-related serious AEs. Hypokalaemia (K +

KW - Aldosterone antagonist

KW - Chronic kidney disease

KW - Heart failure

KW - Hyperkalaemia

KW - Potassium-binding polymer

KW - RLY5016

UR - http://www.scopus.com/inward/record.url?scp=79953720277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953720277&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehq502

DO - 10.1093/eurheartj/ehq502

M3 - Article

C2 - 21208974

AN - SCOPUS:79953720277

VL - 32

SP - 820

EP - 828

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 7

ER -